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j Abstract Objectives To use
growth mixture modelling (GMM)
to identify subgroups of children
with attention deficit hyperactive
disorder (ADHD) who have dif-
ferent pharmacodynamic profiles
in response to extended release
methylphenidate as assessed in a
laboratory classroom setting.
Methods GMM analysis was per-
formed on data from the COMACS
study (Comparison of Methyl-
phenidates in the Analog Class-
room Setting): a large (n = 184)
placebo-controlled cross-over
study comparing three treatment
conditions in the Laboratory
School Protocol (with a 1.5-h cycle
of attention and deportment
assessments). Two orally admin-
istered, once-daily methylpheni-
date (MPH) bioequivalent
formulations [Metadate CD/
Equasym XL (MCD-EQXL) and
Concerta XL (CON)] were com-
pared with placebo (PLA). Re-
sults Three classes of children
with distinct severity profiles in
the PLA condition were identified.
For both MCD-EQXL and CON,
the more severe their PLA symp-
toms the better, the children’s
response. However, the formula-
tions produced different growth
curves by class, with CON having
essentially a flat profile for all
three classes (i.e. no effect of PLA
severity) and MCD-EQXL showing
a marked decline in symptoms
immediately post-dosing in the
two most severe classes compared
with the least severe. Comparison
of daily doses matched for imme-
diate-release (IR) components ac-
counted for this difference.
Conclusion The results suggest
considerable heterogeneity in the
pharmacodynamics of MPH re-
sponse by children with ADHD.
When treatment response for
near-equal, bioequivalent daily
doses the two formulations was
compared, marked differences
were seen for children in the most
severe classes with a strong cur-
vilinear trajectory for MCD-EQXL
related to the greater IR compo-
nent.
j Key words
pharmacodynamics –
pharmacokinetics –
attention deficit/hyperactivity dis-
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Introduction
Methylphenidate (MPH) is an effective treatment [23]
for attention deficit/hyperactivity disorder. The phar-
macodynamics of MPH (i.e. across-the-day changes in
treatment response) has become a focus of major
interest following the development of different con-
trolled-release formulations with particular drug
delivery and pharmacokinetic profiles [3, 20]. Phar-
macodynamic analysis has been facilitated by the
development of a specially designed Laboratory School
Protocol that allows the systematic measurement of
symptoms at multiple points across the day following
drug administration in the morning [18, 21].
Standard pharmacodynamic assessment is based
on a comparison of change in response for all subjects
in a group across different times of the day: this ap-
proach assumes that an individual’s response trajec-
tory is best characterised as being a member of a
single and coherent group of subjects (or latent
pharmacodynamic class). However, we know from
clinical practice and effectiveness trials that, while
MPH is effective in the majority of cases, there are
significant variations between patients in their indi-
vidual treatment responses that require individuali-
sation of dose and dosing regimen [9, 25]. Thus, while
many children have a good response to MPH, a
minority of children do not respond favourably and
the response of most children is less than optimal
[10]. This observation leads us to ask: do variations in
MPH response exist at the level of individuals’
pharmacodynamic profiles in addition to these
well-recognised differences in gross measures of
symptoms aggregated across the whole day? It would
certainly be clinically useful to know whether, for
instance, the symptoms of ADHD are greater in the
morning or the afternoon [2], or whether there are
children who respond better in the morning than the
afternoon, or vice versa. This has not been explored
sufficiently in the literature to date.
There are a number of different ways of studying this
issue. For instance, one might define a particular
pharmacodynamic trajectory on an a priori basis (e.g.
with a positive morning response relative to an after-
noon response) and compare this profile with other
pre-defined pharmacodynamic profiles in terms of
clinical characteristics. An alternative empirically
based approach to identifying pharmacodynamic
subtypes is to use the relatively new statistical tech-
nique of growth mixture modelling (GMM) [12]. The
objective of GMM is to identify whether, within a large
group of subjects, heterogeneity exists in how subjects
change over time. Put another way, instead of one
homogeneous group, GMM asks if the data support the
existence of two or more subgroups of individu-
als—latent classes (LCs)—with different trajectories of
change over time. If so, the task is to identify the
smallest number of LCs with distinct trajectories. GMM
has been used successfully in developmental psycho-
pathology research in a range of settings [24]; however,
the application of GMM in the past has been limited to
analyses of trajectories over relatively long time scales
(months and years; e.g., Cuijpers et al. [7]). GMM is
also well suited to the assessment of heterogeneity in
treatment response over an hour-by-hour time scale, as
is the case with pharmacodynamic analyses of MPH
response described in this paper.
In GMM the trajectory of change over time for each
individual participant is decomposed into its growth
parameters (i.e. intercept, linear, quadratic, etc.).
Standard fit indices, in addition to more subjective
criteria, are then used to compare models with dif-
ferent numbers of LCs in order to decide upon the
optimal solution. GMM has most leverage in terms of
identifying valid LCs within a heterogeneous group of
trajectories if variation within one condition can be
partitioned in terms of performance under a second,
more or less independent, condition. In this sense, a
randomised placebo (PLA)-controlled trial provides a
good vehicle for GMM analyses of MPH pharmaco-
dynamic response, where the heterogeneity in re-
sponse to MPH can be partitioned in terms of LCs
identified by patterns of response growth (change
over time) in the PLA condition.
Here we utilise already existing data from the
large-scale head-to-head COMACS study (Compari-
son of Methylphenidates in the Analog Classroom
Setting [19]) of two controlled-release MPH formu-
lations [Metadate CD/Equasym XL (MCD-EQXL)
and Concerta (CON)]. CON tablets were designed to
replace thrice-daily immediate-release (IR) MPH,
providing up to 12-h symptom coverage, with 22% of
the dose in an IR overcoat and 78% in the extended-
release (ER) core. MCD-EQXL capsules were designed
to replace twice-daily (b.i.d.) regimes of IR MPH and
provide up to 8-h coverage with a ratio of 30% IR to
70% ER MPH beads. Although each formulation re-
sults in essentially the same overall systemic expo-
sure, as evidenced by a comparative area under the
plasma concentration time curve (AUC), when
administered at similar daily doses, the different
delivery profiles of the two formulations result in
distinctly different pharmacokinetic profiles [8]. In
COMACS, as predicted by these pharmacokinetic
profiles, MCD-EQXL produced a greater response up
to 6 h from drug administration, which was attributed
to the 50% larger IR MPH component versus CON for
near-equal daily doses. CON produced superior
control in the early evening (i.e. at 12 h post-dosing
[16, 19]).
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The COMACS data set provides a particularly good
basis for a GMM analysis of pharmacodynamic hetero-
geneity for a number of reasons. First, it has a large
sample that could provide the statistical power neces-
sary to compare the characteristics of individuals within
subsets of participants identified from the sample in
terms of their membership of different growth classes.
Secondly, it includes data derived from observations of
response by trained observers across significant parts of
the day, with the number of observations (n = 7) being
sufficienttoallowarangeofdifferentgrowthparameters
to be estimated (e.g. from linear to cubic). Thirdly, this
trial was designed to provide a within-subject compar-
ison of both formulations against PLA and thus pro-
vided the opportunity to assess heterogeneity in
response to each formulation using the growth classes of
the PLA response condition—a common point of ref-
erence for the analysis. Using the PLA condition in this
way also allows an indirect assessment of the role of
severity after a week of drug withdrawal (at least as
modelled using time-series data from the PLA condition
ina laboratory classroom, whereseverity is measuredby
ratings of attention and deportment on the Swanson,
Kotkin, Atkins, M-Flynn, Pelham [SKAMP] rating
scale). Severity, along with gender, seems to be one of
only a small number of characteristics that are impor-
tant for prediction of MPH response [16]. Therefore,
severity may be an important clinical consideration to
guide choices between formulations with different
dosing profiles. The current analysis represents the first
attempt to model severity using time-series data.
The aims of this re-analysis of the COMACS data,
therefore, were to: (i) employ GMM to identify whe-
ther there are multiple growth trajectories within the
group in the PLA condition and (ii) use the derived
latent growth classes (subgroups) to partition varia-
tions in pharmacodynamic profiles following a
morning dose of MCD-EQXL and CON. The clinical
and background characteristics (titrated dose or
strata, severity, ADHD subtype status, comorbidity,
gender, etc.) of the individuals within the different
growth classes will also be compared, and any dif-
ferences between groups will be controlled in the
comparison of the pharmacodynamic profiles of the
two MPH formulations.
Methods
j Patients
Six- to 12-year-old children, receiving treatment with
doses of MPH between 10 and 60 mg/day (5–20 mg
per administration, one to three times a day) were
recruited for the multi-site COMACS trial. The sub-
jects were screened and enrolled by the principal
investigator at each study site (Appendix 1). Children
were deemed otherwise healthy on the basis of an
extensive medical history and physical examination;
diagnosis of ADHD was confirmed by a clinical re-
search interview carried out by a trained interviewer.
Children were excluded if they had an IQ below 80 or
the inability to follow or understand study instruc-
tions. Other exclusion criteria included severe mental
disorder (e.g. psychosis, bipolar illness, pervasive
developmental disorder, severe obsessive compulsive
disorder, or severe depressive disorder), extreme
aggressive behaviour or destruction of property,
marked anxiety, tension, or agitation. Comorbid psy-
chiatric diagnoses were established at the screening
visit by reference to DSM-IV criteria (see Swanson
et al. [22] for details). A total of 184 patients (48 fe-
male) entered the trial. Eighty-two percent of the pa-
tients met criteria for ADHD-combined type, 15% met
criteria for inattentive type, and the remaining 3% met
criteria for hyperactive/impulsive type. Approximately
25% of the children had a comorbid condition (e.g.,
anxiety and oppositional defiant disorder). At pre-
screening, 9% of the patients were on once-a-day
dosing regimens with extended release MPH prepa-
rations: 54% on the t.i.d. equivalent formulation of
CON and 23% on the b.i.d. equivalent formulation of
MCD-EQXL. Of the remainder, 7.6% were taking b.i.d.
IR MPH and 1.6% t.i.d. IR MPH. The current analysis
was based on 169 patients who participated in all three
treatment conditions. The 15 cases not included in the
sample were slightly younger, F(1, 183) = 7.067,
P < 0.01, and were more likely to have a co-morbid
anxiety disorder v2 (1, n = 185) = 4.65, P < 0.05,
when compared with the rest of the group.
j Design
COMACS was a 10-site, double-blind, placebo-con-
trolled, cross-over study comparing three treatment
conditions: MCD-EQXL, CON and PLA. Dose-level
assignment was made according to the pre-study,
clinically titrated daily dosing regimen for MPH and
remained at that level for the study duration. Children
treated with low doses (£20 mg/day) of MPH were
randomised to receive a daily dose of MCD-EQXL
20 mg, CON 18 mg or PLA; those treated with med-
ium doses (>20–40 mg/day) were randomised to re-
ceive MCD-EQXL 40 mg, CON 36 mg or PLA; and
children treated with high doses (>40 mg/day) were
randomised to receive MCD-EQXL 60 mg, CON
54 mg or PLA. Each of the three treatments was
administered for 7 days (in the assigned sequence)
without an intervening washout period, and the
pharmacodynamic assessment was conducted on the
seventh day of each treatment.
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j Assessment
Assessment took place in the laboratory school on
days 7, 14 and 21 (for a detailed description of the
laboratory classroom facility see [17, 21, 22, 26]). Two
trained observers assessed patients during each
classroom session on the Swanson, Kotkin, Atkins,
M-Flynn, Pelham (SKAMP) scale on the basis of a
1.5-h cycle of activities, with separate assessments of
attention and deportment being made at 0 (i.e., pre-
dose or baseline), 1.5, 3.0, 4.5, 6.0, 7.5 and then 12 h
after drug administration. The laboratory classroom
scores (SKAMP and PERMP) were completed by
dedicated raters at each study site. These raters were
required to complete pre-study standardisation
training administered by UCI staff; however, the in-
ter-rater reliability was not formally assessed.
The SKAMP has six deportment items (e.g. staying
seated, interacting with others) and seven attention
items (e.g. getting started, sticking with tasks). Par-
ents of the children also completed the Swanson,
Nelson & Pelham scale (version IV; [17]), which has
39 items derived from the Diagnostic and Statistical
Manual (DSM) criteria for ADHD and ODD. The
items on this scale are reproduced from DSM-IV and
DSM-III symptoms for ADHD. Parents and teachers
respond on a Likert scale rating the presence of these
symptoms. Making use of only the DSM-IV symp-
toms, the scale yields ADHD-related factor scores for
inattention and hyperactivity–impulsivity.
j Statistical approach
The pharmacodynamics of MCD-EQXL and CON was
studied through two stages. First, the repeatedly as-
sessed ADHD symptom scores during PLA were used
to determine the optimal number of distinct sub-
groups of children through GMM. As described
above, the objective was to determine the smallest
number of subgroups—or latent classes (LCs)—of
children with distinct across-day courses of attention
and deportment. Three criteria are used to determine
the optimal number of LCs. The first is a low Bayesian
information criterion (BIC) [11]. Lower BIC values
indicate a better fit of the model with N LCs when
compared with the N ) 1 LC model. The second is the
usefulness of the LCs, which involves the subjective
interpretation of the developmental course of the
trajectories, and the number of children in each LC.
The third is the stability of the model. This was tested
through the use of different starting values. For each
model, 200 random perturbations of starting values
were generated by the program. A model is stable
when, despite different starting values, similar solu-
tions are obtained. As long as the usefulness and
stability criteria are met, the model with the lowest
BIC value is considered the optimal solution. The
outcomes of the trajectory model are LC membership
probabilities, which give the probabilities of an indi-
vidual belonging to each of the LCs, and the means
and variances of the growth parameters.
The LC membership probabilities were essential
for the second phase of analysis. A child with a high
severity profile across the day would have a high
probability of belonging to a high LC but a low
probability of belonging to a low LC. In the second
phase, we estimated the impact of MCD-EQXL and
CON on the responses of children in each of the
identified PLA LCs. A multiple group GMM model
(e.g., MCD-EQXL versus CON) was run in which the
response curves of children under MCD-EQXL and
CON medication were compared. The Satorra scaled
log-likelihood difference test [14] was used to deter-
mine any significant differences between the phar-
macodynamic trajectories of response across the day
for children within each of the LCs under different
conditions (e.g. MCD-EQXL versus CON). The class
membership probabilities are included in the model
to identify the children in each of the classes. All
analyses were performed with Mplus 4.2 [13]. Dif-
ferences between the formulations in the time-course
of response across the day were tested using analysis
of variance (ANOVA) and multivariate analysis of
variance (MANOVA) models. In these analyses, all
differences between LCs in background and clinical
factors were entered as covariates.
Results
j Identifying the optimal number of classes
To determine the number of growth parameters
needed to model the repeated assessments across the
day in the PLA condition, models with up to four
growth parameters (intercept, linear growth term,
quadratic growth term, cubic growth) were fitted. The
comparative fit index (CFI) and the Tucker Lewis
index (TLI), which take the parsimoniousness of the
model and sample size into account, were used to
determine model fit [4, 5]. Values >0.90 are consid-
ered an adequate fit. Using these criteria, the final
model with four growth parameters (intercept, linear,
quadratic and cubic growth terms) had a good fit to
the data: CFI = 0.96, TLI = 0.97.
We then determined the optimal number of LCs.
Initially, the growth factor variances and covariances
were set to zero, while the variances of the repeat-
edly assessed severity scores were held equal over
time. LC-specific variances/covariances were not
used in this phase of analysis. GMM analyses re-
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vealed a gradual improvement in the fit of the model
with an increase from one to four LCs (BIC 1 LC
= 9,504; BIC 2 LC = 8,794; BIC 3 LC = 8,393; BIC 4
LC = 8,284). Using five or more LCs resulted in the
addition of small LCs with children with low severity
(not meeting the usefulness criterion) or in unstable
or non-converging solutions. We then allowed for
variances in the growth parameters and LC-specific
variances for the three- and four-LC solutions. The
optimal three-LC solution, with LC-specific variances
in a low severity LC and variances on the intercept
and linear term, had a BIC value of 8,123. The BIC of
the optimal four-LC solution was 8,135. We therefore
judged that the across-day course of response was
best described by three distinct trajectory classes of
children.
j Classes of PLA ADHD symptom curves
The mean severity levels at each measurement point
during the day for each LC are shown in Fig. 1. Al-
though different in other growth parameters, these LCs
were characterised most easily by difference in inter-
cept or the overall severity. Twenty-three children
(12.4%) were in a high severity LC, 75 (40.5%) in an
intermediate severity LC and the remaining 71 (38.4%)
in a low severity LC. The characteristics of children in
each of the three severity LCs are presented in Table 1.
There was also an effect of site on LC membership, with
children in the low symptom category being especially
likely to come from two of the study sites. In the original
analyses of COMACS, these two sites were dropped, but
the results did not change from the results of the
analysis including all sites [22]. Therefore, all sites were
included in the current analysis of individual differ-
ences in MPH response. The LCs did not differ in
average titrated dose level. Individuals in the high
severity LC tended to have diagnoses of ADHD-com-
bined type and be male, with an intermediate level of
comorbidity. Those in the intermediate severity LC
tended also to have diagnoses of ADHD-combined type
and be male, but had the highest level of comorbidity.
The individuals in the low severity LC were most likely
to be female, older in age and have a diagnosis of
ADHD-predominantly inattentive type rather than
ADHD-combined type, and very low levels of comor-
bidities. Interestingly, this low severity LC did not differ
from the other two LCs in terms of ratings of symptoms
of ADHD in the natural environment of the home and
school. This suggests that, on average, subjects in all
LCs had equal severity of symptoms of ADHD in their
normal or everyday lives.
Fig. 1 Across the day trajectories for the three latent growth classes derived
using growth mixture modelling of across-day ADHD symptoms for children
under the placebo condition. Values are means ± standard error. The numbers
in each class are: high = 23, intermediate = 75, low = 71 children
Table 1 Age, gender, ADHD subtype and comorbid ODD and anxiety for children in the 3 day-time ADHD latent classes
ADHD latent class Test
High (N = 23) Intermediate (N = 75) Low (N = 71) Statistic df
Age 9.00 (2.20) 9.45 (1.78) 10.17 (1.45) F = 5.30** 2,166
Male sex (%) 82.6 81.3 62.0 v2 = 8.16** 2
Dose level (% high) 15.1 47.2 37.7 v2 = 2.57 4
ADHD symptoms
SNAP inattention 1.26 (0.39) 1.34 (0.51) 1.21 (0.47) F = 1.24 2,166
SNAP hyperactive 1.29 (0.44) 1.24 (0.64) 1.05 (0.49) F = 2.85 2,166
Subtype ADHD (%) v2 = 16.21** 4
Combined 87.0 93.3 69.0
Inattentive 8.7 6.7 22.5
Hyperactive/imp 4.3 0.0 8.5
Comorbidity (%)
ODD 8.7 16.0 1.4 v2 = 9.60** 2
Anxiety 4.3 14.7 2.8 v2 = 7.28* 2
Values in parenthesis are standard deviations
ADHD = attention deficit hyperactivity disorder; ODD = oppositional defiant disorder
* P < 0.05, ** P < 0.01
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j MCD-EQXL and CON pharmacodynamics for children
in each of the PLA growth classes
We then compared the MPH pharmacodynamics for
the two formulations (MCD-EQXL versus CON) for
each of the three identified LCs. The means and
standard errors of the across-the-day response pro-
files for each to the three conditions (PLA, MCD-
EQXL and CON) are plotted in Fig. 2 for children in
each class separately. Differences between MCD-
EQXL and CON were observed in terms of the shape
of the growth curves. CON had essentially a flat
profile for all three LCs, with little difference in
severity at different times of the day. While this was
true for MCD-EQXL for the patients in the low
severity LC (due perhaps to the negligible overall ef-
fect), for those in the intermediate and high severity
LCs the growth trajectory followed a cubic function
with a marked decline in severity immediately post-
dosing relative to CON.
While the visual interpretation of the trajectories
suggests possible differences between the two MPH
formulations, it is important to test whether these
pharmacodynamic differences are statistically sig-
nificant. We performed a number of tests to inves-
tigate this. We first tested whether the trajectories
for the three conditions were different from each
other by holding the four growth parameters
(intercept, linear, quadratic and cubic term) equal
between conditions for each of the three LCs (i.e.
assuming that the within-day course of ADHD
symptoms were similar across conditions). The re-
sults shown in Table 2 suggest that for each of the
three classes the curves reflecting the MPH phar-
macodynamic for MCD-EQXL and CON were both
different from PLA (see Table 2, first and second
row). When comparing near-equal daily doses of
MCD-EQXL and CON with each other (see Table 2,
third row), significant differences in the growth
parameters were again found. This indicates that the
time–response curves were statistically different
from one another in terms of the linear, quadratic
and cubic parameters. These effects remained when
other factors that distinguished the membership of
LCs (age, gender, etc.) were controlled using analysis
of covariance (ANCOVA).
To evaluate which assessment times were respon-
sible for these observed differences, a MANOVA was
conducted (controlling for age, sex, ADHD subtype
and comorbid ODD and anxiety). For each of the
three classes significant time-of-day · condition
interactions were found: F(14, 98) = 4.55, P < 0.01 for
the high severity class; F(14, 410) = 15.46, P < 0.01 for
the intermediate severity class; F(14, 396) = 5.15,
P < 0.01 for the low severity class. Means (SDs) and
post-hoc tests and between the observed severity
scores at each time-point are in Table 3. The results
mainly underscore that for near-equal daily doses,
MCD-EQXL is superior to CON in response early in
the day, soon after administering the drug in the high
and intermediate severity LCs. The predicted superi-
ority for CON at the 12-h point was present only for
Fig. 2 (a–c) Across-day ADHD symptoms for PLA, CON and MCD-EQXL for
children in the three placebo latent growth classes. Values are means ± stan-
dard error. The numbers in each class are: high = 23, intermediate = 75,
low = 71 children
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the intermediate severity LC. The sizes of these effects
are mainly in the medium–large range [6].
This study used a non-equivalence design to
compare the two formulations at near-equal daily
doses that were bioequivalent by usual regulatory
standards (i.e. resulted in equal overall levels of
exposure to MPH across the day). When equated in
this way, the formulations differ markedly in terms
of the relative size of the IR component. The
absolute difference between IR components of the
formulations (in mg) is small, and only small dif-
ferences in response were expected, so a large
sample was required by the COMACS design.
However, at these near-equal doses, MCD-EQXL has
50% more IR MPH in the initial bolus delivery
process than CON (6 vs. 4 mg at the low daily dose,
12 vs. 8 mg at the medium daily dose and 18 vs.
12 mg at the high daily dose), but the same amount
of extended release MPH (for both MCD-EQXL and
CON, 14 mg at the low, 28 mg at the medium or
42 mg at the high daily doses). In order to test
whether the morning advantage of MCD-EQXL in
response was due solely to these differences in the
IR component, as suggested by post-hoc analyses in
the initial COMACS report [22], we conducted a
supplementary cross-dose analysis in which we at-
tempted to control for the IR component of the two
formulations. This was achieved by restricting
analyses to the data from the conditions when
children were given low and medium doses of
MCD-EQXL (with IR components of 6 and 12 mg,
respectively) and medium and high doses of CON
(with IR components of 8 and 12 mg, respectively),
which have near-equal IR components. In order to
maintain statistical power, children from the inter-
mediate and high severity LCs were combined for
this secondary analysis. The findings are shown in
Fig. 3. IR dose was not related to the revised tra-
jectory group membership: v2 (4, n = 226) = 3.56,
P > 0.05. ANOVA showed that differences between
the high/medium dose of CON and the medium/low
Table 2 Test statistics ()2 log-likelihood) for holding growth parameters of
day curve ADHD symptoms equal between conditions, for the three ADHD
classes separately
Class
High Intermediate Low
PLA versus CON 49.97** 138.30** 45.58**
PLA versus MCD-EQXL 109.63** 188.64** 42.02**
CON versus MCD-EQXL 20.96** 42.09** 12.07*
Entries represent )2 log-likelihood difference statistics with four degrees of
freedom
* P < 0.05, ** P < 0.01
Table 3 Means and standard deviations of across the day SKAMP symptom scores for children in the high, intermediate and low latent classes
PLA CON MCD-EQXL Effect size
Time (h) M SD M SD M SD MCD/PLA CON/PLA MCD/CON
High class
0 36.22a 7.32 38.65a 9.08 39.75a 11.49 – – –
1.5 44.52a 6.98 28.22b 12.37 21.52c 10.35 2.61 1.62 0.59
3.0 45.23a 7.86 34.22b 10.55 24.68c 14.09 1.80 1.18 0.77
4.5 44.69a 8.35 35.90b 14.28 30.02b 12.91 1.35 0.75 –
6.0 48.57a 8.44 34.61b 9.37 32.13b 11.05 1.67 1.57 –
7.5 46.75a 10.13 37.74b 12.61 38.39b 11.88 0.76 0.79 –
12 44.83a 8.94 41.50a 11.09 44.59a 11.78 – – –
Intermediate class
0 15.55a 7.81 23.11b 9.71 23.20b 10.53 0.83 0.86 –
1.5 22.87a 7.21 17.32b 10.79 11.89c 7.65 1.48 0.60 0.58
3.0 27.31a 8.97 17.19b 9.97 11.93c 7.46 1.86 1.07 0.60
4.5 27.69a 7.80 18.24b 10.14 13.12c 8.66 1.77 1.04 0.54
6.0 29.57a 7.13 16.91b 11.49 15.89b 9.56 1.62 1.32 –
7.5 29.43a 9.21 18.46b 10.67 18.59b 10.36 1.11 1.10 –
12 24.62a 10.16 19.61b 10.82 23.62a 10.68 – 0.48 0.37
Low class
0 7.91a 5.15 10.93b 5.36 11.65b 7.28 0.59 0.57 –
1.5 8.88a 5.24 6.59b 4.76 5.66b 4.48 0.66 0.46 –
3.0 9.69a 5.71 7.65b 6.12 6.20b 4.98 0.65 0.34 –
4.5 10.24a 5.19 8.08b 6.70 6.77b 5.57 0.64 0.36 –
6.0 11.87a 5.52 7.80b 6.62 8.27b 10.10 0.44 0.67 –
7.5 12.21a 6.63 8.56b 8.04 8.21b 5.56 0.65 0.50 –
12 10.92a 7.00 8.90a 7.58 10.94a 7.64 – – –
M = means, SD = standard deviation
Different superscript letters within rows indicate significant different means SKAMP symptom scroes between treatment condition (PLA, CON, MCD-EQXL), using LCD
correction for multiple testing. Only significant effect sizes are shown (P < 0.05)
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dose of MCD-EQXL formulations at any time-point
for either of the groups of children failed to reach
significance (F<2.37; P = 0.125).
Conclusion
This paper provides the first application of GMM to
explore heterogeneity in the pharmacodynamics of
MPH in ADHD. Overall, the results support the value
of GMM in the analysis of time-series data on the
pharmacodynamic of MPH response as measured in
the Laboratory School Protocol. There are a number
of new insights provided by this novel approach.
First, and most generally, the analyses suggest that the
pharmacodynamic responses of individual patients to
MPH (at least in the COMACS study) may not be best
modelled as a single homogeneous group but rather
as three distinct subgroups (LCs), differing system-
atically from each other in terms of a number of
different characteristics. One subgroup of children
has low levels of severity manifested in the laboratory
classroom across the day in the PLA condition, and
children in this subgroup are more likely to be older,
female and diagnosed with ADHD-predominantly
inattentive type with low levels of comorbidity. This
group shows a rather flat pharmacodynamic profile
on both MPH formulations, suggesting that while
both had a significant effect on symptoms, these ef-
fects were much smaller in size than for the other two
subgroups (LCs), as would expected given their al-
ready low levels of severity in the laboratory class-
room. A second LC had a moderate level of severity
and a growth curve marked by quadratic and cubic
growth parameters. This LC tended to contain more
complex and comorbid cases than either of the other
two classes. Members of this LC showed a larger
response to MPH in general than was shown by the
members of the low severity LC; there was also a
marked differentiation between the two formulations,
with MCD-EQXL showing an initial superiority to
CON at 1.5–4.5 h post-drug intake, but the opposite
being the case at 12 h post-intake. The final class was
marked by the highest severity at baseline (time zero)
on the PLA day of the trial, which increased further
over the laboratory school day. This high severity
subgroup (LC) showed the largest treatment effects
relative to PLA. A comparison across LCs revealed
that the difference in pharmacodynamic profiles for
the two formulations increase with severity of the LC,
due to CON having a similar flat profile for all three
LCs, while MCD-EQXL superiority in the morning
increased with severity that defined the LCs. The
reasons for these different effects of pharmacody-
namic response to MPH as a function of LC require
further investigation. To test whether this difference
in reduction in ADHD symptoms was due to differ-
ences in IR dose between the two drugs, IR dose was
equated by removing children on the high MCD-
EQXL dose or the low CON dose; some differences at
the high levels persisted. When this was conducted, as
predicted, there were no significant differences be-
tween the two formulations in the early part of the
day, even in the combined severe group. This finding
highlights the role of the greater IR dose in MCD-
EQXL in determining its early morning superiority in
the more severe groups seen in the main analysis.
A recent paper reported a significant sex difference
in pharmacodynamic in the COMACS study, with
girls showing a more intense initial effect and a
shorter duration of action for both MPH formulations
[16]. At first sight, this result seems to stand in con-
trast to the current finding, in which girls were most
likely to occupy the class that showed the smallest
response to MPH in general. However, the results of
these two analyses are not comparable. In the gender
difference analysis reported previously [16], the ef-
fects of sex emerged only after large differences
severity at baseline and in the PLA condition were
controlled. In the current analysis the gender dis-
parity between the PLA groups was controlled before
the efficacy of CON and MCD-EQXL were compared.
j Limitations
The current study has a number of limitations. Al-
though COMACS is one of the largest studies using
the Laboratory School Protocol ever conducted, the
statistical power to explore differences was still rela-
tively low, due to the fractionation of the sample into
subgroups of children identified on the basis of their
growth class membership. The differences reported
Fig. 3 Across-day ADHD symptoms for CON and MCD-EQXL, controlled for IR
dose, for children in the high/intermediate (combined) and low latent growth
classes. Values are means ± standard error. The numbers in the two groups
were: intermediate combined = 98 (23 + 75) children, low = 71 children
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here may underestimate the effects, especially for the
high severity subgroup (LC), which was comprised of
the lowest number of children. The Laboratory School
Protocol employed in the current study employs
surrogate measures of children’s behaviour set in a
specialised environment. The importance of this issue
for the current study is highlighted in relation to the
subgroup (LC) consisting of participants who dis-
played low levels of severity within the laboratory
classroom on the PLA condition. This was slightly
surprising, as all children were assessed rigorously
prior to entry into the study and all met the full
diagnostic criteria for ADHD; there was no difference
between LCs in terms of parents’ ratings of symptoms
of ADHD outside the laboratory classroom setting.
There are at least four possible interpretations of this
result: first, that the SKAMP and the SNAP measure
different aspects of ADHD symptoms even when used
in the same setting and context. Second, that the two
sites with especially low SKAMP scores contributed
differentially to this group [22]. Third, that the low
severity LC were placebo responders—although the
fact that the LC differences in severity occurred at
time zero just before dosing is not consistent with this
view. Fourth, this apparent discrepancy between
diagnostic assessment and the low PLA scores is due
to the laboratory school setting, with high levels of
structure and good staff:student ratio, which was
therapeutically beneficial. This could be tested by
examining the pharmacodynamic profiles in a more
naturalistic setting using repeated measurements of
symptoms according to the same time schedule as
that used in the laboratory classroom, as suggested by
Antrop et al. [2]. The current study had unusually low
levels of severe comorbid disorders for an ADHD
treatment trial, probably as a result of the exclusion
criteria used. The impact of including the most severe,
complex cases on the pasterns of heterogeneity and as
associated MPH responses could not be established in
this study and requires further research.
The design of the COMACS study, and especially
the selection of comparator doses for different for-
mulations and release profiles of the same drug, has
been a subject of considerable debate. The main is-
sue relates to what are the dosing equivalents for
MCD-EQXL and CON. In the COMACS, bioequiva-
lent total daily doses were used as the basis for
matching the two formulations, and a non-equiva-
lence design was employed to test for pharmacody-
namic differences relating to a small absolute
difference in the IR components of the formulations
(e.g. 4 vs. 6 mg; 8 vs. 12 mg; 12 vs. 18 mg). An
alternative design suggested by Adesman [1] would
match formulations based on IR to give a ‘‘fair’’
comparison, but this would require a strategy of
accepting the null hypothesis of no difference rather
than rejecting the null hypothesis as in the COMACS
design [19]. After rejecting the null hypothesis, post-
hoc analyses were used to compare doses of the two
formulations equated in terms of their IR compo-
nents (see [15, 19] for discussion). In similar post-
hoc analyses reported here, differences in the two
formulations in the morning could not be demon-
strated, but the sample size may be too small to
accept the null hypothesis of non-difference.
j Clinical implications
Different patients appear to respond in different ways
to extended release MPH formulations in general.
This highlights the importance of evaluating indi-
vidual differences in the pharmacodynamics of MPH
response when considering treatment options for
children with ADHD. In particular, it appears that for
comparison of bioequivalent and near-equal daily
doses, children with high levels of severity may ben-
efit particularly from the drug delivery profile of
MCD-EQXL with its larger IR component than the
drug delivery profile of CON.
How best to assess individual differences in drug
response needs careful consideration. In the current
study, the subgroups with different response profiles
were identified on the basis of performance in the
PLA condition in the laboratory classroom and not
on the basis of parent or teacher ratings in normal
settings. Further research is required to identify
more cost-effective ways of assessing individual
differences in MPH response that have both pre-
dictive power and can be used in everyday clinical
practice. Finally, the current analysis highlights the
potential role of statistical techniques such as GMM
to further our knowledge about subpopulations who
may respond more favourably to particular treat-
ments.
Appendix 1
Investigators enrolling patients
Site no. Name of investigator Address
01 Joseph Biederman, MD Massachusetts General Hospital
02 Ann Childress, MD Nevada Behavioral Health, Inc.
03 Flemming Graae, MD New York Presbyterian Hospital
04 Laurence Greenhill, MD New York State Psychiatric Institute
05 Scott Kollins, PhD Duke Family and Child Clinic
06 Frank Lopez, MD Children’s Developmental
Center, Maitland, FL
07 Sharon Wigal, PhD UCI Child Development Center
10 Eliot Moon, MD Elite Clinical Trials, Inc.
11 John Turnbow, MD Behavioral Neurology, Suite A Lubbock
12 Matthew Brams, MD Bayou City Research, Ltd.
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